Navigation Links
Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
Date:2/5/2009

ISIS-SGLT2Rx - Isis' first kidney-targeted antisense drug for type 2 diabetes enters clinical development

CARLSBAD, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS-SGLT2Rx, an antisense drug that inhibits the production of sodium dependent glucose co-transporter type 2 (SGLT2). SGLT2 is the major transporter responsible for glucose re-absorption in the kidney. Decreasing SGLT2 levels promotes glucose excretion in the urine and reduces blood sugar levels, making it an attractive target for the treatment of diabetes. The Phase 1 study of ISIS-SGLT2Rx is a double-blind, placebo-controlled, dose-escalation study conducted in healthy volunteers and is designed to assess the safety and pharmacokinetic profile of ISIS-SGLT2Rx as well as to measure ISIS-SGLT2Rx's activity by evaluating its effect on glucose excretion in urine.

"In several preclinical models, we have demonstrated greater than 80 percent reduction of SGLT2 levels in the kidney at low-weekly doses, which resulted in significant increases in urinary glucose excretion. These changes were accompanied by robust and sustained decreases in blood glucose levels in diabetic animals as well as amelioration of diabetic complications such as cataract formation. Furthermore, ISIS-SGLT2Rx did not reduce blood sugar levels below normal," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Diseases Research & Development at Isis. "We are encouraged by the preclinical activity of ISIS-SGLT2Rx and the high tissue-specificity observed for our first kidney-targeted drug."

"ISIS-SGLT2Rx is among the most potent antisense drugs Isis has yet evaluated in preclinical models. The enhanced potency we have observed supports the possibility of infrequent injectable dosing or
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...swire-FirstCall/ -- IES (Nasdaq: IESC ), a leadin...ns systems and services for the commercial, indust... its commercial business group has been awarded a ...lectrical systems for the Level 4 bio-safety lab (...al Research Institute of Infectious Diseases (USAM...
(Date:11/24/2009)... Iceland, November 24 de...d that it has received notice from,the Nasdaq Stoc...k will be,suspended as of November 30, 2009 and a ...Exchange Commission, which will remove deCODE,s co...any files an appeal to the Nasdaq,Listing Qualific...
(Date:11/24/2009)... 24 NeurogesX, Inc. (Nas...on developing and commercializing novel pain manag...nno, President and Chief Executive Officer, is sch... Health Care Conference, to be held December 1-2, ... York. ,, Mr. DiTonno and Stephen Ghiglieri, C...
(Date:11/24/2009)...RONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton T...Inc., a leading provider of advanced laser systems...rtility clinic markets, today reported operational... September 30, 2009. , , Q3 2009 Highlights, ...43 million in Q3 2008, - Gross profit margin ...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
... To date, 60 specialty & fine,chemical and custom ...duled,to exhibit at the Pharma ChemOutsourcing Con...y., The conference and exhibition has already att...t September. The supplier community is attracted t...gh ratio of attendees from,pharmaceutical and biop...
...n by Dr. John St. John -, - Three Poster Present... ADDISON, Texas, May 28 ULURU Inc. (Amex: ULU ),...materials Congress, to be,held in Amsterdam from M...s,Vice President of Material Science, will give an...tion of three posters., The title of the invited ...
...ve Three Oncology Products in Clinic -, - Lead Ca...n-Small Cell Lung Canc...y 28th, at 11:00 a.m. Pacific ...y 28 /PRNewswire-FirstCall/ - Sonus,Pharmaceutical...s Inc., a,privately held biopharmaceutical develop...
Other Biology Technology:60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey 2ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3Sonus Pharmaceuticals and OncoGenex Technologies to Merge 2Sonus Pharmaceuticals and OncoGenex Technologies to Merge 3Sonus Pharmaceuticals and OncoGenex Technologies to Merge 4Sonus Pharmaceuticals and OncoGenex Technologies to Merge 5Sonus Pharmaceuticals and OncoGenex Technologies to Merge 6Sonus Pharmaceuticals and OncoGenex Technologies to Merge 7Sonus Pharmaceuticals and OncoGenex Technologies to Merge 8
(Date:11/23/2009)...s that a common oral bacterium may exacerbate auto...al, "Unique Lipids from a Common Human Bacterium R...hancing Autoimmunity," appears in the December 200... Multiple sclerosis (MS), a disease where the imm...cts nearly 1 in 700 people in the United States. ...
(Date:11/23/2009)...ailable for the H1N1 virus has been sent to vaccin...ination marks the first time vaccine has been sent..., Iowa State University,s Hank Harris, professor ...er and has been shipping preventive doses to swine...l weeks., The latest vaccines were shipped to a ...
(Date:11/23/2009)...E and USDA study concluded that 50 million U.S. ac...re could be converted from current uses to the pro... from which biomass could be harvested for use as ...n of a perennial grass monoculture from which subs... is expected to require nitrogen fertilizer. , A...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 1Child Care Centers Throughout Mexico Being Crucified Unjustly Says Interchildren Inc 52045 2Senators Baucus and Grassley Statement Regarding Physician Hospitals Despicable 52040 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 1Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 2Covanta Mendota Recognized for Its Exemplary Health and Safety Practices 52036 3
...CMay 28, 2008The 2008 American Society for Microbi...nvestigator Award is being presented to Adrian M. ...nfectious Diseases, NIAID, National Institutes of ...plied research in clinical microbiology or antimic...work studying infection susceptibility and resista...
...Man international scientific and professional orga...promoting the practical applications, technology a...nehas awarded $300,000 in research grants to suppo...ed by SNM,s Education and Research Foundation, rep...ular imaging and therapy by supporting the next ge...
..., R.I. July 14, 2008 The outlook for air quality... there,s little that the Chinese government can do... University of Rhode Island atmospheric chemist wh...the last five years by Chinese scientists. , "Th...nent to the pollutants that cause unhealthy air in...
Other Biology News:SNM awards $300,000 to support molecular imaging research 2URI researcher: China can't fully fix air quality problem for Olympics 2
Mouse Anti-Human SNAPC5 Monoclonal Antibody, Unconjugated, Clone 6G10 from Abnova Corporation
AGAROSE II (LOW MELT) from Pierce Biotechnology, Inc.
...sed against a partial recombinant NFKBIB. Immun...l recombinant protein with GST tag. Protein Seq...LHLAAILGETSTVEKLYAAGAGLCVAERRGHTALHLACRVGAHACARA ...: AAH15528 OMIM: 604495, GeneID: 4793 ...
Mouse Anti-Human CRKRS Monoclonal Antibody, Unconjugated, Clone 2F6 from Abnova Corporation
Biology Products: